Inogen (INGN) Scheduled to Post Earnings on Tuesday

Inogen (NASDAQ:INGN) is scheduled to release its earnings data after the market closes on Tuesday, May 7th. Analysts expect Inogen to post earnings of ($0.76) per share for the quarter. Inogen has set its Q1 2024 guidance at EPS.Parties interested in participating in the company’s conference call can do so using this link.

Inogen (NASDAQ:INGN) last announced its quarterly earnings data on Tuesday, February 27th. The medical technology company reported ($1.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.49). Inogen had a negative net margin of 32.46% and a negative return on equity of 38.98%. The firm had revenue of $75.90 million for the quarter, compared to analysts’ expectations of $78.09 million. On average, analysts expect Inogen to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Inogen Stock Performance

Shares of NASDAQ INGN opened at $7.15 on Friday. The firm’s 50 day moving average price is $7.16 and its 200 day moving average price is $6.45. The firm has a market cap of $168.38 million, a P/E ratio of -1.62 and a beta of 1.10. Inogen has a 1 year low of $4.13 and a 1 year high of $13.86.

Analyst Ratings Changes

Several research firms have recently issued reports on INGN. William Blair upgraded Inogen from a “market perform” rating to an “outperform” rating in a report on Thursday, February 15th. Needham & Company LLC reissued a “hold” rating on shares of Inogen in a research note on Tuesday, April 9th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $7.50.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.